Home > Resources > Whitepapers > Risk assessment of fungal materials

Cell and Gene Therapy, Industrial Impact

Risk assessment of fungal materials

February 24, 2022

Sustainable fungal materials have a high potential to replace non-sustainable materials such as those used for packaging or as an alternative for leather and textile.

Spotlight

PooyaGene Biotech Co.

PooyaGene Biotech Company is a research- and knowledge-driven enterprise. The company commenced its operation as a R&D unit in 2007, set up by some talented Iranian professionals to settle a state-of-the-art company to offer the high quality production and services in Biotechnology and Bioinformatics. In 2009, the R&D unit successfully qualified to pursue its activity in a Science and Technology Incubator Center in Iran. PooyaGene Biotech Company - Officially registered in 2010- later in 2011, to expand its collaboration with overseas pharmaceutical and biotech companies started its business operation in India.

OTHER WHITEPAPERS

Genetic insights for biopharmaceuticals: Propelling drug candidates into therapeutic assets

whitePaper | March 9, 2023

For biopharmaceutical and biotechnology companies, innovation is imperative. Economic growth in these industries relies heavily upon investment in product development—perhaps more so than any other industry

COVID-19 Vaccines Production and Analytical Chemistry Solutions

whitePaper | February 2, 2022

Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO).

Early engagement and regulatory considerationsfor biotech

whitePaper | May 10, 2022

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines

Automated Extraction of High Molecular Weight DNA

whitePaper | November 14, 2019

SmartExtraction significantly simplifies the entire automated workflow of DNA extraction, setting new standards with regard to efficiency, yield and quality of the DNA.

Next-Generation Technology, Procedures, and Products Facilitate Biopreservation Best Practices for Cellular Therapies.

whitePaper | August 19, 2022

The quality of procedures and products used for preparing, transporting and storing cells at cryogenic temperatures have a direct impact on post-thaw viability and functionality, as well as the consistency and reliability of biological agents from a Quality perspective.

Cell and Gene Therapy, Industrial Impact

Risk assessment of fungal materials

Spotlight

PooyaGene Biotech Co.

OTHER WHITEPAPERS

Genetic insights for biopharmaceuticals: Propelling drug candidates into therapeutic assets

COVID-19 Vaccines Production and Analytical Chemistry Solutions

Considerations for migrating a drug product presentation from vial to pre-filled syringe

Early engagement and regulatory considerationsfor biotech

Automated Extraction of High Molecular Weight DNA

Next-Generation Technology, Procedures, and Products Facilitate Biopreservation Best Practices for Cellular Therapies.

Genetic insights for biopharmaceuticals: Propelling drug candidates into therapeutic assets

COVID-19 Vaccines Production and Analytical Chemistry Solutions

Considerations for migrating a drug product presentation from vial to pre-filled syringe

Early engagement and regulatory considerationsfor biotech

Automated Extraction of High Molecular Weight DNA

Next-Generation Technology, Procedures, and Products Facilitate Biopreservation Best Practices for Cellular Therapies.

Spotlight

PooyaGene Biotech Co.

Events